BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining$35 million anticipated to close in Q1 2026.BioAtla to retain 65% ownership of Oz-V across all solid tumor indications after completion of the SPV transaction.BioAtla will lead Phase 3 trial execution for Oz-V in OPSCC through data readout for potential accelerated approval and enrollment anticipated to begin early 2026.Oz-V targets ROR2, an important receptor ...